



Press release, Tuesday, March 8, 2016

Novo A/S announces an expansion of its large investment portfolio through an investment in ERT alongside Nordic Capital Fund VIII.

ERT is the leading provider of high-quality electronic data collection solutions for clinical drug development programs, and their systems are widely used by pharmaceutical and biotech companies innovating drug and device therapies. Headquartered in Philadelphia, PA, United States, the company and its 1200 employees support more than 1500 clinical trials globally, capturing in excess of 400,000 patients, on an annual basis. ERT delivers a unique combination of technology, services and clinical consulting, built on a foundation of deep scientific and regulatory expertise. ERT's solutions increase the accuracy and reliability of the patient data collected in healthcare areas such as cardiac safety and respiratory function as well as within electronic clinical outcome assessments.

Commenting on the investment in ERT, Michael Shalmi, Head of Large Investments in Novo A/S ("Novo"), said:

"It's a core part of Novo's investment strategy to finance well-established and profitable life-science companies with a leading position in their field and good growth potential. ERT is a great company with a clear leadership position, which has innovated and developed the field of electronic clinical data capture and assessments, and has strong track record and customer endorsements."

The investment in ERT, which is a global leader within the clinical trials services industry, marks the expansion of Novo's focus for its large investments to include United States.

"Together with Nordic Capital Fund VIII we look forward to supporting the continued development and growth of ERT in the coming years, as outlined in the exciting business plan presented by the leadership of ERT led by Jim Corrigan, president and chief executive officer," he continued.

Novo and Nordic Capital Fund VIII ("Nordic Capital") have acquired the ownership of ERT from Genstar Capital, with Nordic Capital as the controlling shareholder. As a long-term investor, Novo, together with Nordic Capital will provide significant backing for ERT to pursue a continued expansion of its operations and business model. The investment by Novo, into the Nordic Capital controlled ERT, is the first investment collaboration between the parties.

Commenting on this partnership, Jonas Agnblad, Partner, NC Advisory, advisor to the Nordic Capital Funds stated:

"We look forward to developing our investment partnership with Novo A/S, and to welcome them into the ownership group of ERT. Nordic Capital and Novo both have substantial healthcare investment experiences, which they each will deploy to the further development of ERT."

Completion of the investment is subject to customary regulatory approval. Further details of the transaction will not be disclosed.

Advisors to Novo on the transaction included Plesner, and PwC.

For more information:

Novo A/S Michael Shalmi	+ 45 30 674 785 mish@novo.dk
Nordic Capital Katarina Janerud	+46 8 440 50 50 katarina.janerud@nordiccapital.com

Notes to Editors

About Novo A/S

Novo A/S, the holding company in the Novo Group, is responsible for the management of the assets of the Novo Nordisk Foundation, which are currently valued at more than USD 40 billion. Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation. Besides being the major shareholder in Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies, within life science and biotechnology, as well as manages a broad portfolio of financial assets. For further information visit www.novo.dk

About ERT

ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information see www.ert.com

About Nordic Capital

Nordic Capital private equity funds have invested in mid-market companies primarily in the Nordic region since 1989. Through committed ownership and by targeting strategic development and operational improvements, Nordic Capital enables value creation in its investments. Nordic Capital Funds invest in companies in northern Europe and in selected investment opportunities internationally. The most recent fund is Nordic Capital Fund VIII with EUR 3.5 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Funds are based in Jersey, Channel Islands, and are advised by the NC Advisory companies in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital please see www.nordiccapital.com